Nafamostat mesylate
Nafamostat mesylate, a synthetic serine protease inhibitor, that contains antiviral and anti-cancer properties, used to treat acute pancreatitis. It is apowerful MERS- inhibitor that obstructs membrane fusion, was found inhibitive to 2019-nCoV infection when tested in EC50 = 22,50 μM, CC50 > 100 μM, SI> 4,44 concentration rate, suggested for further studies [10]. As per the researchers at the University of Tokyo, Nafamostat will prevent the fusion of the virus envelope with the host cell surface proteins, the first step in infection with SARS-CoV-2 at one-tenth of the concentration provided by Camostat mesylate (Foypan), which was recently described by a German group as a SARS-CoV-2 inhibitor [39].